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Abstract
Background: Both obesity and mental health are major public health issues. This study aimed to examine whether
overweight and obesity among midlife employees are associated with subsequent psychotropic medication. A
further aim was to examine the potential effect of key covariates on the association.
Methods: The Helsinki Health Study baseline survey was conducted in 2000–2002 among 40–60-year-old
employees of the City of Helsinki, Finland (n = 8960). The participants were classified as of normal weight (18.5–24.
9 kg/m2), overweight (25–29.9 kg/m2), obese (30–34.9 kg/m2) or severely obese (≥35 kg/m2) based on self-reported
body mass index. Data on psychotropic medication purchases from baseline to 2009 were derived from registers of
the Social Insurance Institution of Finland. The final analysis included 4760 women and 1338 men. Antidepressants
and sedatives were examined separately. Covariates included socio-demographic factors, workload, health
behaviours, physical functioning, somatic ill-health and psychotropic medication prior to baseline. Hazard ratios (HR)
for the first psychotropic medication purchase were calculated using Cox regression analysis.
Results: Third of women and quarter of men made at least one psychotropic medication purchase during the
follow-up. Adjusting for age, obese (HR = 1.57; 95 % CI = 1.10–2.24) and severely obese (HR = 2.15; 95 % CI = 1.29–3.
56) men were at risk of having psychotropic medication compared to men of normal weight. These associations
disappeared after further adjustment. Severe obesity remained associated with subsequent sedative medication
among the men even after full adjustment (HR = 2.12; 95 % CI = 1.17–3.84). No associations were found among the
women.
Conclusions: Obese and severely obese men, but not women, were at risk of psychotropic medication. Further
studies are needed to deepen understanding of the relationship between obesity and mental ill-health, and the
possible protecting effects of age, employment, and living environment.
Keywords: Obesity, Overweight, Body mass index, Psychotropic medication, Mental ill-health, Register data,
Follow-up, Ageing employee
Background
Both obesity and mental ill-health are major public-
health issues worldwide. In Finland, as in many other
Western countries, one fifth of adults are obese and
one tenth are regular users of psychotropic medication
[1–4]. Previous studies have shown that both obesity
and mental ill-health are likely independently to constitute
risks for somatic diseases, poor quality of life, work dis-
ability and mortality [1, 5, 6].
The majority of relevant cross-sectional studies have
shown an association between obesity and mental ill-
health in the form of depression, anxiety, and suicide
attempts and ideation among women [5–9], but some
studies, especially among men, report no association
[5–8]. Besides obesity also metabolic syndrome has
been shown to be associated with mental ill-health
[10]. The majority of longitudinal studies suggest that
the association is reciprocal, supporting an association
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between obesity and subsequent mental ill-health [11–13].
It was shown in a meta-analysis that both overweight and
obesity increase the risk of subsequent depression [11]
and a review based on ten follow-up studies reported that
in eight of them obesity was associated with subsequent
depression [12]. However, in half of the reviewed studies
the follow-up for obesity started in childhood or adoles-
cence, in two of them the association disappeared follow-
ing adjustment for baseline depression, and in one study
on adolescents the association was found only among
women [12]. The majority of the ten studies adjusted for
sex, age, and education and half of the studies adjusted for
marital status, somatic health, and smoking. However,
only two studies adjusted for alcohol and three for phys-
ical activity.
In contrast with the majority of previous studies the
most recent longitudinal studies report no or weak asso-
ciations between obesity and subsequent mental ill-
health [14–17]. According to a Finnish study, a high
BMI among women, but not among men, predicted de-
pressive symptoms, but the associations among women
attenuated after adjustment for smoking and alcohol
consumption [14]. In the largest follow-up study to date,
obesity among female nurses in the US was found to
predict self-reported depression or antidepressant use.
The associations attenuated, but remained, following ad-
justments for baseline depression and age, comorbidities,
health behaviours, and other covariates [13]. It was re-
ported in another study among Baltimore adults that
obesity did not increase the risk for depression or anx-
iety disorder, although an increased risk for suicide at-
tempts was identified [14]. Similarly, a recent study
using Mendelian randomisation reported no causal asso-
ciation between obesity and depression [16]. Longitu-
dinal studies focusing on the association between obesity
and anxiety disorder have also shown inconsistent re-
sults [6].
Our aim in this study was to provide a different perspec-
tive on the association and to find out whether baseline
obesity among Finnish public-sector employees is associ-
ated with subsequent psychotropic medication. Only a few
previous studies have focused on employed European
adults, and many fail to adjust for earlier mental ill-health,
socio-demographic and work- and health-related covari-
ates. We considered age, socio-economic position, marital
status, workload, smoking, alcohol consumption, physical
activity, physical functioning, and somatic ill-health as
key covariates as these factors are associated with men-
tal ill-health and are often unequally distributed be-
tween the body mass index groups [18–21]. Moreover,
given that most previous studies relied mainly on self-
reported mental-health data, we offer a further perspec-
tive on the association between obesity and mental
health by using register-based data on prescribed
psychotropic medication. Our main aim was to investi-
gate the potential association of overweight and obesity
with subsequent psychotropic medication among mid-
life female and male employees. We also wanted to find
out whether socio-demographic and work- and health-
related covariates affected the associations, and whether
there were differences between antidepressant and seda-
tive medication.
Methods
Data
The Helsinki Health Study baseline mail surveys were
conducted in 2000–2002 among 40–60-year-old em-
ployees of the City of Helsinki, Finland. There were 8960
respondents (response rate 67 %). Corresponding to the
gender distribution in the Finnish municipal sector, 78 %
of these respondents were women. Men, younger em-
ployees and manual workers were slightly underrepre-
sented, but according to our non-response analyses, the
data satisfactorily represent the target population [22].
Data on prescribed reimbursed psychotropic medication
purchases from 1995 to 2009 were derived from registers
of the Social Insurance Institution of Finland. The
follow-up started from the day of returning the survey
questionnaire and lasted until the end of 2009, the date
of purchase of the psychotropic medication, or death
(n = 176). The mean follow-up time was 6.4 years. The
register data included the date of purchase, the type of
prescribed medication and the amount in defined daily
doses (DDD). Seventy-four per cent of the participants
gave consent to the register linkages. According to our
non-response analyses, employees from lower occupa-
tional and income classes were somewhat underrepre-
sented, but the differences were small and are unlikely
to cause a major bias in the results [23].
The 319 persons who were taking psychotropic medi-
cation at baseline were excluded. Further exclusions in-
cluded 15 pregnant women, 58 underweight (BMI
<18.5 kg/m2) individuals and 135 persons with missing
information on some of the variables. Thus the final
analysis included 6098 participants, of whom 78 % were
women.
The ethics committees of the Department of Public
Health, the University of Helsinki and the health author-
ities of the City of Helsinki approved the Helsinki Health
Study protocol.
Measures
Body mass index
We calculated the BMI (kg/m2) based on self-reported
weight (kg) and height (m). We used the WHO (World
Health Organization) recommendation in defining normal
weight as 18.5–24.9 kg/m2, overweight as 25–29.9 kg/m2,
obesity as 30–34.9 kg/m2 and severe obesity as ≥35 kg/m2.
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Psychotropic medication
Prescribed, reimbursed psychotropic medication pur-
chases, psychotropic medication in brief, was classified
according to the Anatomical Therapeutic Chemical
(ATC) system [24]. We included any psychotropic medi-
cation within the ATC classification N05 and N06 except
anti-dementia medication (N06D), which we excluded.
Antidepressants (N06A), sedatives (including anxiolytics
[NO5B] and hypnotics and pure sedatives [NO5C]) were
examined separately. The first prescribed, reimbursed
psychotropic medication purchase during the follow-up
implied psychotropic medication.
Covariates
The respondents were classified into five age groups
based on age at baseline: 40, 45, 50, 55 and 60 years. So-
cioeconomic position was derived from the employer’s
register and categorised into managers and professionals,
semi-professionals, routine non-manual employees and
manual workers [25]. Marital status included those who
lived with a partner versus others. Workload was self-
reported and categorised as physically and mentally
strenuous or non-strenuous work. Leisure-time physical
activity was measured in line with Metabolic Equivalent
values (MET) [26], including four categories ranging
from physically inactive to vigorously active [20]. Smok-
ing at baseline was classified into current smokers and
non-smokers. Drinking problems as measured on the
CAGE questionnaire [27] included problem drinking
and no problem drinking (the cut-off scores were two
and three points for women and men, respectively). The
physical functioning score from the Short-Form 36 ques-
tionnaire [28] was divided into quintiles, the lowest
quintile representing poor physical functioning. Somatic
ill-health was considered to be present if the respondent
reported ever having been diagnosed with gout, arthro-
sis, rheumatoid arthritis, angina pectoris, myocardial in-
farction, cerebral circulation disturbance, claudication or
epilepsy. Participants with at least one psychotropic
medication purchase during a period of 5 years before
baseline were categorized as prior psychotropic medica-
tion users. Participants who did not report problem drink-
ing (n = 194), smoking (n = 36) or marital status (n = 26)
were classified as not problem drinkers, non-smokers and
singles, respectively. Respondents giving no information
on workload (n = 99) were included in the non-strenuous
category.
Statistical methods
Cross-tabulation was initially used to describe the data.
Kaplan-Meier curves were calculated to estimate the
proportions of different weight groups with no psycho-
tropic medication. Hazard ratios (HR) and 95-per-cent
confidence intervals (95 % CI) for the first purchase of
any psychotropic medication during the follow-up were
calculated using Cox regression analysis. In addition, an-
tidepressants and sedatives were examined separately.
Normal weight was the reference category in all the ana-
lyses. Model 1 was adjusted for age and model 2 for age
and previous psychotropic medication. Model 3 was also
adjusted for covariates, including socio-economic pos-
ition, marital status, physical and mental strenuousness
of work, physical activity, smoking, and drinking be-
haviour. Model 4 was additionally adjusted for phys-
ical functioning and somatic ill-health. Women and
men were examined separately. We used Schoenfeld’s
residuals to confirm Cox proportional hazards as-
sumptions. The analyses were performed using IBM
SPSS Statistics 22.
Results
Half of the women were of normal weight and a third
were overweight (Table 1). About ten per cent of the
women and the men were obese. As the Kaplan-Meier
curves showed, obese and severely obese men were more
likely than others to have had any psychotropic medica-
tion during the follow-up (Fig. 1). However, among the
women the curves are descending at almost the same
rate, suggesting only minor differences in psychotropic
medication between the BMI groups.
A third of the women and a quarter of the men had
taken some psychotropic medication during the follow-
up (Table 2). The prevalence of antidepressant medica-
tion showed vague, but non-significant, trend to increase
with increasing BMI among the women, whereas there
was no such increase in the case of sedative medication.
Among the men, psychotropic medication was more
common among the obese (27 %) and the severely obese
(38 %) than among those of normal weight (21 %). The
prevalence of sedative medication increased with in-
creasing BMI, being highest among the severely obese
men (33 %).
We performed Cox regression analysis adjusting for
covariates. Testing for gender interaction showed that
the associations between BMI and any psychotropic
medication (p = 0.04 for interaction) as well as sedatives
(p = 0.01) were significantly different among the women
and the men, whereas, for antidepressants the associa-
tions were similar (p = 0.44). Following adjustment for
age, the obese (HR = 1.57; 95 % CI = 1.10–2.24) and se-
verely obese (HR = 2.15; 95 % CI = 1.29–3.56) men were
at risk of having some psychotropic medication during
the follow-up compared to men of normal weight
(model 1) (Table 3). The obesity risk weakened following
adjustment for earlier psychotropic medication (model 2).
Further adjustments in model 3 attenuated the risk for the
severely obese (HR = 1.51; 95 % CI = 0.90–2.53). The asso-
ciation did not persist after additional adjustment for
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physical functioning and somatic health (model 4). When
antidepressants and sedative medication were examined
separately there were no associations for antidepressants
among the men. However, obese (HR = 1.69; 95 % CI =
1.09–2.63) and severely obese (HR = 3.09; 95 % CI = 1.77–
5.39) men were at risk of having sedative medication after
adjustment for age. Further adjustment for previous psy-
chotropic medication attenuated the association, which
lost statistical significance among the obese. However, for
the severely obese the association remained even after full
adjustment (model 4) (HR = 2.12; 95 % CI = 1.17–3.84).
No association was found among overweight men.
The associations between BMI and subsequent psy-
chotropic medication were weak and non-significant
among the women (Table 3). A weak association was
found with antidepressants among the obese (HR = 1.20;
95 % CI = 0.99–1.46) and severely obese (HR = 1.32;
95 % CI = 0.95–1.82), but it disappeared after adjustment
for the covariates.
Discussion
Principal findings
We examined the association between body mass index
and subsequent psychotropic medication among midlife
employees. Obesity and especially severe obesity were
associated with having some psychotropic medication
among the men, but the association attenuated following
adjustment for previous psychotropic medication and
other covariates. However, the association between severe
obesity and sedatives among the men remained after
Table 1 The distributions of the variables by BMI groups
Body mass index (kg/m2)a
Women (N = 4760) Men (N = 1338)
Normal weight Overweight Obese Severely obese Total Normal weight Overweight Obese Severely obese Total
% % % % % % % % % %
Total 53 32 11 3 100 39 45 12 4 100
Age (years)
40 25 17 17 14 21 22 18 11 4 18
45 24 20 18 19 22 22 20 15 21 20
50 22 22 20 21 22 19 20 20 38 20
55 21 26 32 32 24 26 27 37 23 28
60 9 15 14 14 12 12 16 19 15 15
Married/cohabiting 69 70 67 60 69 79 79 76 65 78
Socioeconomic position
Managers/professionals 37 45 47 53 41 9 9 9 17 9
Semi-professionals 22 18 16 13 20 20 20 21 15 20
Routine non-manual 33 24 22 19 28 49 44 35 35 45
Manual workers 9 13 16 16 11 21 27 36 33 26
Physically strenuous work 34 41 43 44 38 16 14 17 19 15
Mentally strenuous work 75 76 77 74 76 74 75 70 71 74
Smoker 21 23 20 21 21 24 24 33 27 25
Drinking problem 15 16 14 14 15 22 23 32 19 23
Physical activity (MET)
Inactive 18 25 38 48 24 20 25 44 56 26
Moderately active 38 42 41 34 40 33 32 31 25 32
Vigorously active 29 26 17 16 26 27 23 17 13 23
Highly active 15 8 4 2 11 21 20 8 6 18
Poor physical functioning 9 20 33 44 17 15 20 43 67 23
Somatic health problem 17 26 29 37 22 16 22 29 42 21
Psychotropic medication
before baseline
19 23 26 21 21 11 14 21 25 14
a Body mass index was categorised into four groups: normal weight 18.5–24.9 kg/m2, overweight 25–29.9 kg/m2, obese 30–34.9 kg/m2 and severely
obese ≥35 kg/m2
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adjustment. We found no association between BMI and
subsequent psychotropic medication among the women.
Previous studies
The majority of previous studies indicate an association
between obesity and subsequent mental ill-health, find-
ings that have been particularly consistent among
women. We found no associations among the women,
however, and only weak associations among the men.
There are some differences to be noted when the results
of this study based on prescribed, reimbursed psycho-
tropic medication purchases are compared with earlier
studies based mainly on self-reported mental-health
data. First, our measure may be less sensitive to mental
ill-health in that a medical prescription is based on a
professional examination made by a physician in addition
to symptoms reported by the patient. However, the thresh-
old for prescribing psychotropic medication is probably
quite low in Finland: the majority of common mental
disorders are treated by general practitioners and access to
reimbursed rehabilitative psychotherapy is restricted, and
is first considered after 3 months of other appropriate
treatment. Second, psychotropic medication for the obese
may be affected by physicians’ preconceptions of obese
people. It has been reported that physicians may consider
obese people less motivated and compliant than patients
of normal weight [29], and it is therefore possible that
mental health among the obese is less likely to be treated
as a medical problem. Third, obese people are more likely
than those of normal weight to show other somatic health
problems that require medical treatment, whereby psycho-
tropic medication might be avoided due to the risk of drug
interaction. Fourth, the threshold for consulting a doctor
on account of mental ill-health might be higher among
the obese than among those of normal weight. According
to the results of one study, 84 % of obese participants
agreed that “weight is blamed for most medical problems”
[30]. However, the obese may have more regular contact
Table 2 Psychotropic medication by BMI groups during the follow-up
Body mass index (kg/m2)a
Normal
weight
Overweight Obese Severely obese Total P-valueb
% (N) % (N) % (N) % (N) % (N)
Women 54 (2545) 32 (1525) 11 (530) 3 (160) 100 (4760)
Any psychotropic medication 31 (796) 32 (489) 32 (169) 36 (58) 32 (1512) 0.61
Antidepressants 21 (524) 22 (329) 23 (124) 25 (40) 21 (1017) 0.32
Sedatives 19 (493) 20 (300) 18 (95) 21 (33) 19 (921) 0.81
Men 39 (524) 45 (607) 12 (159) 4 (48) 100 (1338)
Any psychotropic medication 21 (108) 23 (138) 27 (43) 38 (18) 23 (307) <0.05
Antidepressants 15 (76) 16 (97) 18 (28) 23 (11) 16 (212) 0.41
Sedatives 12 (65) 15 (89) 18 (29) 33 (16) 15 (199) <0.01
a Body mass index was categorised into four groups: normal weight 18,5–24.9 kg/m2, overweight 25–29.9 kg/m2, obese 30–34.9 kg/m2 and severely obese ≥35 kg/m2
b Chi-square test for proportions
Fig. 1 Estimated proportions of women and men with no psychotropic medication by BMI groups: Kaplan-Meier curves
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with healthcare professionals on account of their somatic
health, and thus their mental disorders could more easily
be noticed.
In contrast to the majority of previous studies, the par-
ticipants in our study were employed at baseline. There
is one earlier study from the US that also focused on
employees, but only female nurses were included and
the participants were older, with an average age of 65
and most of them were probably no longer employed
[13]. It is possible that work environments protect the
obese from developing mental ill-health, given that the
employed have been shown to have better health than
the non-employed [31]. A recent study, using the same
data, examined joint associations of BMI and leisure-
time physical activity with psychotropic medication and
suggested that physical activity dominates the associ-
ation over normal-weight [32]. It is possible that
employed people have healthier lifestyle e.g. less alcohol
use and more exercise, which might partly protect them
against mental ill-health. In further studies it would be
interesting to compare employees with non-employed in
order to study the differences in life style and the pos-
sible protective effect of employment.
Another difference from the majority of earlier studies
is that our cohort focused on midlife people. Age has
been discussed as both a protective and a risk factor for
Table 3 The association of BMI with any subsequent psychotropic medication as well as antidepressant and sedative medication:
Cox regression analysis (hazard ratios, HR, and their 95 % confidence intervals (95 % CI)
Model 1 Model 2 Model 3 Model 4
BMI (kg/m2)a HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Any psychotropic medication
Women Normal weight 1.00 - 1.00 - 1.00 - 1.00 -
Overweight 1.06 0.95–1.19 1.00 0.89–1.12 0.97 0.87–1.09 0.94 0.84–1.06
Obese 1.05 0.89–1.24 0.93 0.78–1.10 0.90 0.76–1.06 0.84 0.71–1.00
Severely obese 1.23 0.94–1.61 1.23 0.94–1.61 1.16 0.89–1.53 1.03 0.79–1.36
Men Normal weight 1.00 - 1.00 - 1.00 - 1.00 -
Overweight 1.18 0.91–1.51 1.14 0.88–1.47 1.12 0.87–1.44 1.09 0.84–1.41
Obese 1.57 1.10–2.24 1.37 0.96–1.97 1.26 0.87–1.82 1.15 0.79–1.66
Severely obese 2.15 1.29–3.56 1.76 1.06–2.92 1.51 0.90–2.53 1.19 0.70–2.03
Antidepressants
Women Normal weight 1.00 - 1.00 - 1.00 1.00 -
Overweight 1.10 0.96–1.26 1.05 0.91–1.20 1.00 0.86–1.15 0.96 0.83–1.11
Obese 1.20 0.99–1.46 1.08 0.89–1.32 1.02 0.83–1.25 0.94 0.77–1.16
Severely obese 1.32 0.95–1.82 1.29 0.93–1.77 1.15 0.83–1.60 1.01 0.72–1.40
Men Normal weight 1.00 - 1.00 - 1.00 - 1.00 -
Overweight 1.17 0.87–1.58 1.12 0.83–1.52 1.10 0.81–1.49 1.09 0.80–1.48
Obese 1.44 0.93–2.22 1.20 0.77–1.86 1.05 0.67–1.65 0.95 0.60–1.50
Severely obese 1.78 0.94–3.37 1.36 0.72–2.59 1.10 0.57–2.11 0.93 0.48–1.80
Sedatives
Women Normal weight 1.00 - 1.00 - 1.00 - 1.00 -
Overweight 1.01 0.88–1.17 0.95 0.82–1.09 0.92 0.80–1.07 0.92 0.79–1.06
Obese 0.91 0.73–1.13 0.79 0.64–0.99 0.78 0.62–0.98 0.76 0.61–0.95
Severely obese 1.07 0.75–1.53 1.06 0.74–1.50 1.04 0.73–1.49 0.99 0.69–1.43
Men Normal weight 1.00 - 1.00 - 1.00 - 1.00 -
Overweight 1.26 0.91–1.73 1.26 0.91–1.73 1.27 0.92–1.75 1.21 0.87–1.68
Obese 1.69 1.09–2.63 1.50 0.96–2.34 1.44 0.91–2.27 1.38 0.88–2.19
Severely obese 3.09 1.77–5.39 2.61 1.49–4.55 2.44 1.38–4.31 2.12 1.17–3.84
a Body mass index (BMI) was categorised into four groups: normal weight 18.5–24.9 kg/m2, overweight 25–29.9 kg/m2, obese 30–34.9 kg/m2 and severely
obese ≥35 kg/m2
Model 1: Adjusted for age
Model 2: Adjusted for age and previous psychotropic medication
Model 3: Adjusted for covariates in model 2, socio-demographic factors, health behaviours and strenuousness of work
Model 4: Adjusted for covariates in model 3, physical functioning and somatic health
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mental ill-health among the obese. It is suggested in a
recent longitudinal study that the associations could be
weaker among adults on account of improved emotional
regulation and less stigmatisation associated with weight
by age [15]. However, different views have also been pre-
sented, and a Finnish study has identified an association
between advancing age and lower levels of body satisfac-
tion on many aspects of body image [14, 33]. The study
also showed that women associated their body mass
index with their body image more strongly than men. It
was therefore unexpected in our study that the associ-
ation between obesity and mental ill-health was stronger
among the men. However, the prevalence of psycho-
tropic medication was higher among the women in our
cohort, and it is possible that mental ill-health is per-
ceived and treated differently among women and men,
which might weaken the associations among women.
In contrast to the majority of earlier research, some re-
cent studies [14–17] somewhat in line with our results,
report no association between obesity and subsequent
mental ill-health among women. It could be that the in-
creased prevalence of obesity has changed people’s atti-
tudes and made obesity more acceptable. Reducing the
stigma attached to weight could positively affect self-
esteem among the obese and protect against mental ill-
health [34]. However, an extensive review did not pro-
duce evidence of a decrease in the stigmatisation of
obesity [29], although it did show some differences be-
tween European countries compared with the US and
Australia. Given such differences between countries, it
would be interesting in further studies to focus on how
the neighbourhood environment and culture contribute
to the stigmatisation of weight and thus the association
between obesity and mental health.
Methodological considerations
The main strength of this study lies in the use of exten-
sive prospective data (n = 6098) including employed
women and men with different occupations and back-
grounds. Another strength is the long follow-up time
(a mean of 6.4 years). A third strong point is the use of
reliable register data on prescribed psychotropic medica-
tion, including all prescribed reimbursed psychotropic
medication purchased in pharmacies in Finland. Pre-
scribed psychotropic medication from registers reflects
mental health and provides data that avoids self-report
bias. The register data on psychotropic medication have
previously been used in order to examine associations be-
tween mental health and e.g. physical activity, workplace
bullying, traffic noise, and marital status [20, 35–37].
However, our study population included only one, al-
beit large, municipal employer and is restricted to mid-
life employees. Height and weight measurements as well
as the covariates are based on self-reports: people tend
to underestimate their weight and to overestimate their
height. However, self-reported BMI has been shown to
predict sickness absence equally accurately as measured
BMI [38]. The severely obese were few in number
(n = 209), but the results did not differ from the ten per
cent with the highest BMI. We also divided BMI into
quartiles in the sensitivity analyses, instead of following
the WHO recommendation, but this did not affect the
results, either. The baseline-survey response rate was ac-
ceptable, but non-response remains a problem, and those
under psychotropic medication may be overrepresented
among the non-respondents.
A limitation with the data on medication is that the
register does not include information on psychotropic
medication that was prescribed but not purchased, or
not reimbursed. We also lack information on the clinical
indication of the prescribed medication. In some cases
antidepressants are used to treat insomnia, chronic pain,
premenstrual syndrome and anxiety disorder, whereas
sedatives can be used during sudden life crises to treat
insomnia or seizures, as well as anxiety. According to
our sensitivity analyses, single prescriptions were evenly
distributed over the weight groups, and even when 365
DDD was used as a cut-off point to indicate long-term
psychotropic medication the results were similar. Given
the overlapping of the clinical indication of the medica-
tion we decided to focus on psychotropic medication in
general, and in addition examine antidepressants and
sedatives separately. Because the indication of sedatives
is varied, we carried out additional analyses separating
anxiolytics (N05B) and pure sedatives (N05C, including
sedatives and hypnotics). We found no association with
anxiolytics among the men, but there was an association
with pure sedatives. Sedative use could be related to
sleep disorders such as obstructive sleep apnoea, which
is a relatively common but frequently undiagnosed dis-
order among obese, middle-aged men [39]. Further stud-
ies are therefore needed to examine the association
between psychotropic medication and sleep disorders,
especially among obese men.
The Kaplan-Meier curves (Fig. 1) were steeper during
the first year, suggesting a time-dependent association.
However, when tested on the basis of Schoenfeld’s resid-
uals the Cox proportional hazard assumptions held.
Nonetheless, we carried out a sensitivity analysis in
which the follow-up was cut off at 5 years, and the asso-
ciations were only marginally stronger and again disap-
peared following adjustment. It is possible that adjusting
for physical functioning and somatic health leads to
over-adjustment in that physical health could also medi-
ate the examined associations. For this reason we did
not include physical health in model 3, although even
when adjusted only for covariates in model 3, the statis-
tical significance was lost.
Svärd et al. BMC Psychiatry  (2016) 16:185 Page 7 of 9
Conclusions
In conclusion, obesity and severe obesity were associated
with subsequent psychotropic medication among the
men, but the associations disappeared following ad-
justment for previous psychotropic medication and
other covariates. However, the association between
severe obesity and sedatives remained following ad-
justment. Obesity was not associated with subsequent
psychotropic medication among the women. This
calls for further studies to deepen understanding of
the relationship between obesity and mental health,
and to examine the possible protective effect of em-
ployment, age and the living environment. Further
research is also needed to examine the indications
and factors affecting the prescription of psychotropic
medication.
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